1. Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population. (20th May 2020) Authors: Augustin, M.; Dauden, E.; Mrowietz, U.; Konstantinou, M.P.; Gerdes, S.; Rissler, M.; Gathmann, S.; Sieder, C.; Baeumer, D.; Orsenigo, R. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 11(2020) Page Start: 2548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. (1st July 2020) Authors: Augustin, M.; Dauden, E.; Mrowietz, U.; Konstantinou, M.P.; Gerdes, S.; Kingo, K.; Szepietowski, J.C.; Perrot, J.L.; Cuccia, A.; Rissler, M.; Gathmann, S.; Sieder, C.; Orsenigo, R.; Jagiello, P.; Bachhuber, T. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 2(2021) Page Start: 431 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗